A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.
Identifieur interne : 001149 ( PubMed/Curation ); précédent : 001148; suivant : 001150A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.
Auteurs : Catherine L. Gallagher [États-Unis] ; Bradley T. Christian ; James E. Holden ; Onofre T. Dejesus ; Robert J. Nickles ; Laura Buyan-Dent ; Barbara B. Bendlin ; Sandra J. Harding ; Charles K. Stone ; Barb Mueller ; Sterling C. JohnsonSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2011.
English descriptors
- KwdEn :
- Aged, Brain (radionuclide imaging), Dihydroxyphenylalanine (analogs & derivatives), Dihydroxyphenylalanine (diagnostic use), Dihydroxyphenylalanine (pharmacokinetics), Female, Fluorine Radioisotopes (diagnostic use), Humans, Male, Middle Aged, Parkinson Disease (pathology), Parkinson Disease (radionuclide imaging), Severity of Illness Index, Tomography, Emission-Computed, Tyrosine (analogs & derivatives), Tyrosine (diagnostic use), Tyrosine (pharmacokinetics).
- MESH :
- chemical , analogs & derivatives : Dihydroxyphenylalanine, Tyrosine.
- chemical , diagnostic use : Dihydroxyphenylalanine, Fluorine Radioisotopes, Tyrosine.
- chemical , pharmacokinetics : Dihydroxyphenylalanine, Tyrosine.
- pathology : Parkinson Disease.
- radionuclide imaging : Brain, Parkinson Disease.
- Aged, Female, Humans, Male, Middle Aged, Severity of Illness Index, Tomography, Emission-Computed.
Abstract
Progression of Parkinson's disease symptoms is imperfectly correlated with positron emission tomography biomarkers for dopamine biosynthetic pathways. The radiopharmaceutical 6-[(18) F]fluoro-m-tyrosine is not a substrate for catechol-O-methyltransferase and therefore has a more favorable uptake-to-background ratio than 6-[(18) F]fluoro-L-dopa. The objective of this study was to evaluate 6-[(18) F]fluoro-m-tyrosine relative to 6-[(18) F]fluoro-L-dopa with partial catechol-O-methyltransferase inhibition as a biomarker for clinical status in Parkinson's disease. Twelve patients with early-stage Parkinson's disease, off medication, underwent Unified Parkinson Disease Rating Scale scoring, brain magnetic resonance imaging, and 3-dimensional dynamic positron emission tomography using equivalent doses of 6-[(18) F]fluoro-m-tyrosine and 6-[(18) F]fluoro-L-dopa with tolcapone, a catechol-O-methyltransferase inhibitor. Images were realigned within subject, after which the tissue-derived uptake rate constant was generated for volumes of interest encompassing the caudate nucleus, putamen, and subregions of the putamen. We computed both bivariate (Pearson) and partial (covariate of age) correlations between clinical subscores and tissue-derived uptake rate constant. Tissue-derived uptake rate constant values were correlated between the radiopharmaceuticals (r = 0.8). Motor subscores were inversely correlated with the contralateral putamen 6-[(18) F]fluoro-m-tyrosine tissue-derived uptake rate constant (|r| > 0.72, P < .005) but not significantly with the 6-[(18) F]fluoro-L-dopa tissue-derived uptake rate constant. The uptake rate constants for both radiopharmaceuticals were also inversely correlated with activities of daily living subscores, but the magnitude of correlation coefficients was greater for 6-[(18) F]fluoro-m-tyrosine. In this design, 6-[(18) F]fluoro-m-tyrosine uptake better reflected clinical status than did 6-[(18) F]fluoro-L-dopa uptake. We attribute this finding to 6-[(18) F]fluoro-m-tyrosine's higher affinity for the target, L-aromatic amino acid decarboxylase, and the absence of other major determinants of the uptake rate constant. These results also imply that L-aromatic amino acid decarboxylase activity is a major determinant of clinical status.
DOI: 10.1002/mds.23778
PubMed: 21638324
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001149
Links to Exploration step
pubmed:21638324Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.</title><author><name sortKey="Gallagher, Catherine L" sort="Gallagher, Catherine L" uniqKey="Gallagher C" first="Catherine L" last="Gallagher">Catherine L. Gallagher</name><affiliation wicri:level="1"><nlm:affiliation>William S. Middleton Veterans Hospital, Madison, Wisconsin, USA. gallagher@neurology.wisc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>William S. Middleton Veterans Hospital, Madison, Wisconsin</wicri:regionArea></affiliation></author><author><name sortKey="Christian, Bradley T" sort="Christian, Bradley T" uniqKey="Christian B" first="Bradley T" last="Christian">Bradley T. Christian</name></author><author><name sortKey="Holden, James E" sort="Holden, James E" uniqKey="Holden J" first="James E" last="Holden">James E. Holden</name></author><author><name sortKey="Dejesus, Onofre T" sort="Dejesus, Onofre T" uniqKey="Dejesus O" first="Onofre T" last="Dejesus">Onofre T. Dejesus</name></author><author><name sortKey="Nickles, Robert J" sort="Nickles, Robert J" uniqKey="Nickles R" first="Robert J" last="Nickles">Robert J. Nickles</name></author><author><name sortKey="Buyan Dent, Laura" sort="Buyan Dent, Laura" uniqKey="Buyan Dent L" first="Laura" last="Buyan-Dent">Laura Buyan-Dent</name></author><author><name sortKey="Bendlin, Barbara B" sort="Bendlin, Barbara B" uniqKey="Bendlin B" first="Barbara B" last="Bendlin">Barbara B. Bendlin</name></author><author><name sortKey="Harding, Sandra J" sort="Harding, Sandra J" uniqKey="Harding S" first="Sandra J" last="Harding">Sandra J. Harding</name></author><author><name sortKey="Stone, Charles K" sort="Stone, Charles K" uniqKey="Stone C" first="Charles K" last="Stone">Charles K. Stone</name></author><author><name sortKey="Mueller, Barb" sort="Mueller, Barb" uniqKey="Mueller B" first="Barb" last="Mueller">Barb Mueller</name></author><author><name sortKey="Johnson, Sterling C" sort="Johnson, Sterling C" uniqKey="Johnson S" first="Sterling C" last="Johnson">Sterling C. Johnson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="doi">10.1002/mds.23778</idno><idno type="RBID">pubmed:21638324</idno><idno type="pmid">21638324</idno><idno type="wicri:Area/PubMed/Corpus">001149</idno><idno type="wicri:Area/PubMed/Curation">001149</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.</title><author><name sortKey="Gallagher, Catherine L" sort="Gallagher, Catherine L" uniqKey="Gallagher C" first="Catherine L" last="Gallagher">Catherine L. Gallagher</name><affiliation wicri:level="1"><nlm:affiliation>William S. Middleton Veterans Hospital, Madison, Wisconsin, USA. gallagher@neurology.wisc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>William S. Middleton Veterans Hospital, Madison, Wisconsin</wicri:regionArea></affiliation></author><author><name sortKey="Christian, Bradley T" sort="Christian, Bradley T" uniqKey="Christian B" first="Bradley T" last="Christian">Bradley T. Christian</name></author><author><name sortKey="Holden, James E" sort="Holden, James E" uniqKey="Holden J" first="James E" last="Holden">James E. Holden</name></author><author><name sortKey="Dejesus, Onofre T" sort="Dejesus, Onofre T" uniqKey="Dejesus O" first="Onofre T" last="Dejesus">Onofre T. Dejesus</name></author><author><name sortKey="Nickles, Robert J" sort="Nickles, Robert J" uniqKey="Nickles R" first="Robert J" last="Nickles">Robert J. Nickles</name></author><author><name sortKey="Buyan Dent, Laura" sort="Buyan Dent, Laura" uniqKey="Buyan Dent L" first="Laura" last="Buyan-Dent">Laura Buyan-Dent</name></author><author><name sortKey="Bendlin, Barbara B" sort="Bendlin, Barbara B" uniqKey="Bendlin B" first="Barbara B" last="Bendlin">Barbara B. Bendlin</name></author><author><name sortKey="Harding, Sandra J" sort="Harding, Sandra J" uniqKey="Harding S" first="Sandra J" last="Harding">Sandra J. Harding</name></author><author><name sortKey="Stone, Charles K" sort="Stone, Charles K" uniqKey="Stone C" first="Charles K" last="Stone">Charles K. Stone</name></author><author><name sortKey="Mueller, Barb" sort="Mueller, Barb" uniqKey="Mueller B" first="Barb" last="Mueller">Barb Mueller</name></author><author><name sortKey="Johnson, Sterling C" sort="Johnson, Sterling C" uniqKey="Johnson S" first="Sterling C" last="Johnson">Sterling C. Johnson</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Brain (radionuclide imaging)</term><term>Dihydroxyphenylalanine (analogs & derivatives)</term><term>Dihydroxyphenylalanine (diagnostic use)</term><term>Dihydroxyphenylalanine (pharmacokinetics)</term><term>Female</term><term>Fluorine Radioisotopes (diagnostic use)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (pathology)</term><term>Parkinson Disease (radionuclide imaging)</term><term>Severity of Illness Index</term><term>Tomography, Emission-Computed</term><term>Tyrosine (analogs & derivatives)</term><term>Tyrosine (diagnostic use)</term><term>Tyrosine (pharmacokinetics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dihydroxyphenylalanine</term><term>Tyrosine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Dihydroxyphenylalanine</term><term>Fluorine Radioisotopes</term><term>Tyrosine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Dihydroxyphenylalanine</term><term>Tyrosine</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Brain</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term><term>Tomography, Emission-Computed</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Progression of Parkinson's disease symptoms is imperfectly correlated with positron emission tomography biomarkers for dopamine biosynthetic pathways. The radiopharmaceutical 6-[(18) F]fluoro-m-tyrosine is not a substrate for catechol-O-methyltransferase and therefore has a more favorable uptake-to-background ratio than 6-[(18) F]fluoro-L-dopa. The objective of this study was to evaluate 6-[(18) F]fluoro-m-tyrosine relative to 6-[(18) F]fluoro-L-dopa with partial catechol-O-methyltransferase inhibition as a biomarker for clinical status in Parkinson's disease. Twelve patients with early-stage Parkinson's disease, off medication, underwent Unified Parkinson Disease Rating Scale scoring, brain magnetic resonance imaging, and 3-dimensional dynamic positron emission tomography using equivalent doses of 6-[(18) F]fluoro-m-tyrosine and 6-[(18) F]fluoro-L-dopa with tolcapone, a catechol-O-methyltransferase inhibitor. Images were realigned within subject, after which the tissue-derived uptake rate constant was generated for volumes of interest encompassing the caudate nucleus, putamen, and subregions of the putamen. We computed both bivariate (Pearson) and partial (covariate of age) correlations between clinical subscores and tissue-derived uptake rate constant. Tissue-derived uptake rate constant values were correlated between the radiopharmaceuticals (r = 0.8). Motor subscores were inversely correlated with the contralateral putamen 6-[(18) F]fluoro-m-tyrosine tissue-derived uptake rate constant (|r| > 0.72, P < .005) but not significantly with the 6-[(18) F]fluoro-L-dopa tissue-derived uptake rate constant. The uptake rate constants for both radiopharmaceuticals were also inversely correlated with activities of daily living subscores, but the magnitude of correlation coefficients was greater for 6-[(18) F]fluoro-m-tyrosine. In this design, 6-[(18) F]fluoro-m-tyrosine uptake better reflected clinical status than did 6-[(18) F]fluoro-L-dopa uptake. We attribute this finding to 6-[(18) F]fluoro-m-tyrosine's higher affinity for the target, L-aromatic amino acid decarboxylase, and the absence of other major determinants of the uptake rate constant. These results also imply that L-aromatic amino acid decarboxylase activity is a major determinant of clinical status.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21638324</PMID><DateCreated><Year>2011</Year><Month>09</Month><Day>20</Day></DateCreated><DateCompleted><Year>2012</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2015</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>11</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>2032-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.23778</ELocationID><Abstract><AbstractText>Progression of Parkinson's disease symptoms is imperfectly correlated with positron emission tomography biomarkers for dopamine biosynthetic pathways. The radiopharmaceutical 6-[(18) F]fluoro-m-tyrosine is not a substrate for catechol-O-methyltransferase and therefore has a more favorable uptake-to-background ratio than 6-[(18) F]fluoro-L-dopa. The objective of this study was to evaluate 6-[(18) F]fluoro-m-tyrosine relative to 6-[(18) F]fluoro-L-dopa with partial catechol-O-methyltransferase inhibition as a biomarker for clinical status in Parkinson's disease. Twelve patients with early-stage Parkinson's disease, off medication, underwent Unified Parkinson Disease Rating Scale scoring, brain magnetic resonance imaging, and 3-dimensional dynamic positron emission tomography using equivalent doses of 6-[(18) F]fluoro-m-tyrosine and 6-[(18) F]fluoro-L-dopa with tolcapone, a catechol-O-methyltransferase inhibitor. Images were realigned within subject, after which the tissue-derived uptake rate constant was generated for volumes of interest encompassing the caudate nucleus, putamen, and subregions of the putamen. We computed both bivariate (Pearson) and partial (covariate of age) correlations between clinical subscores and tissue-derived uptake rate constant. Tissue-derived uptake rate constant values were correlated between the radiopharmaceuticals (r = 0.8). Motor subscores were inversely correlated with the contralateral putamen 6-[(18) F]fluoro-m-tyrosine tissue-derived uptake rate constant (|r| > 0.72, P < .005) but not significantly with the 6-[(18) F]fluoro-L-dopa tissue-derived uptake rate constant. The uptake rate constants for both radiopharmaceuticals were also inversely correlated with activities of daily living subscores, but the magnitude of correlation coefficients was greater for 6-[(18) F]fluoro-m-tyrosine. In this design, 6-[(18) F]fluoro-m-tyrosine uptake better reflected clinical status than did 6-[(18) F]fluoro-L-dopa uptake. We attribute this finding to 6-[(18) F]fluoro-m-tyrosine's higher affinity for the target, L-aromatic amino acid decarboxylase, and the absence of other major determinants of the uptake rate constant. These results also imply that L-aromatic amino acid decarboxylase activity is a major determinant of clinical status.</AbstractText><CopyrightInformation>Copyright © 2011 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gallagher</LastName><ForeName>Catherine L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>William S. Middleton Veterans Hospital, Madison, Wisconsin, USA. gallagher@neurology.wisc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christian</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Holden</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Dejesus</LastName><ForeName>Onofre T</ForeName><Initials>OT</Initials></Author><Author ValidYN="Y"><LastName>Nickles</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Buyan-Dent</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bendlin</LastName><ForeName>Barbara B</ForeName><Initials>BB</Initials></Author><Author ValidYN="Y"><LastName>Harding</LastName><ForeName>Sandra J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Charles K</ForeName><Initials>CK</Initials></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Barb</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1UL1RR025011</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD003352</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025011</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025011-03</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025011-04</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025011-05</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>2C598205QX</RegistryNumber><NameOfSubstance UI="C043437">fluorodopa F 18</NameOfSubstance></Chemical><Chemical><RegistryNumber>42HK56048U</RegistryNumber><NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>63-84-3</RegistryNumber><NameOfSubstance UI="D004295">Dihydroxyphenylalanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 1988 Mar;29(3):363-9</RefSource><PMID Version="1">3126278</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52</RefSource><PMID Version="1">2841426</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1990 Oct;28(4):547-55</RefSource><PMID Version="1">2132742</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10993-7</RefSource><PMID Version="1">1438304</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1992 Nov 27;597(1):151-4</RefSource><PMID Version="1">1477728</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Appl Radiat Isot. 1993 Mar;44(3):527-36</RefSource><PMID Version="1">8472025</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1994 Jul;44(7):1292-7</RefSource><PMID Version="1">8035933</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 1996 Apr;119 ( Pt 2):585-91</RefSource><PMID Version="1">8800950</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1997 Jan;41(1):58-64</RefSource><PMID Version="1">9005866</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Life Sci. 1997;60(26):2399-406</RefSource><PMID Version="1">9199484</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1998 Aug;51(2):520-5</RefSource><PMID Version="1">9710028</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 1998 Nov;39(11):1884-91</RefSource><PMID Version="1">9829576</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 1999 Mar;19(3):278-87</RefSource><PMID Version="1">10078880</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 1999 Apr;40(4):102S-123S</RefSource><PMID Version="1">10210232</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>CNS Drugs. 2005;19(2):165-84</RefSource><PMID Version="1">15697329</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2005 Mar;62(3):467-72</RefSource><PMID Version="1">15767513</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Jul;21(7):958-63</RefSource><PMID Version="1">16550545</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Ther. 2006 Oct;14(4):564-70</RefSource><PMID Version="1">16829205</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2008 May 20;70(21):1980-3</RefSource><PMID Version="1">18401019</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2008 Dec 24;28(52):14320-8</RefSource><PMID Version="1">19109513</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2009 Nov 17;73(20):1662-9</RefSource><PMID Version="1">19828868</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 2000 Oct;165(2):342-6</RefSource><PMID Version="1">10993693</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 2001 Apr;21(4):469-76</RefSource><PMID Version="1">11323532</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2001 Jul;16(4):608-15</RefSource><PMID Version="1">11481683</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 2002 Feb;22(2):232-9</RefSource><PMID Version="1">11823721</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2003 Jul;54(1):93-101</RefSource><PMID Version="1">12838524</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2003 Oct;18 Suppl 7:S43-51</RefSource><PMID Version="1">14531046</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Synapse. 2004 May;52(2):153-62</RefSource><PMID Version="1">15034921</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm. 1979;45(2):81-105</RefSource><PMID Version="1">381583</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 1985 Dec;5(4):584-90</RefSource><PMID Version="1">4055928</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Can J Neurol Sci. 1987 Aug;14(3 Suppl):444-7</RefSource><PMID Version="1">3119181</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004295">Dihydroxyphenylalanine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000031">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005462">Fluorine Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014055">Tomography, Emission-Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014443">Tyrosine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000031">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS352210</OtherID><OtherID Source="NLM">PMC3278160</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2011</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23778</ArticleId><ArticleId IdType="pubmed">21638324</ArticleId><ArticleId IdType="pmc">PMC3278160</ArticleId><ArticleId IdType="mid">NIHMS352210</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001149 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001149 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:21638324
|texte= A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:21638324" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |